Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy

Inclusion criteria

• Male or female, 35-65 years old.
• Chronic coronary artery disease with coronary Stenosis detectable by percutaneous coronary intervention (PCI). Ineligibility for percutaneous revascularization, as assessed by coronary arteriography. Ineligibility for percutaneous revascularization procedures was determined by 2 expert committees: a surgical committee comprising 2 cardiovascular surgeons and a noninvasive cardiologist, and an interventional committee comprising 2 interventional cardiologists and 1 noninvasive cardiologist.
• MRI confirmed that chronic coronary artery disease and ischemic regions.
• Left ventricular ejection fraction (LVEF)≤40%.
• NYHA Class II-IV.
• No organ dysfunction for lung, liver and kidney.
• Patients are able and willing to observe therapeutic effect and adverse events.
• Signed informed consent.
• Negative serum pregnancy test.
• No coagulation dysfunction.
• Glycated hemoglobin ≤6.5.

Exclusion criteria

• Lactating or pregnant woman.
• Ineligibility for CABG.
• Unexplainable baseline laboratory abnormalities.
• Sensitivity to any of the study medications.
• Acute myocardial infarction within 1 months of enrollment in the study.
• Patients suffering cardiovascular disease, such as aortic disease, malignant arrhythmias, congenital heart disease, intracardiac mass, moderate or severe valvular stenosis or regurgitation.
• History of life threatening allergic or immune-mediated reaction.
• Systemic infection or severe local infection.
• Shock or MODS or patients cannot cooperate with doctors.
• Severe heart, lung, liver or renal dysfunction.
• Taking medicine that might have effect on outcomes assess.
• Suffering HIV, Hepatitis B or Hepatitis C.
• Participation in any clinical trial in recent three months.
• History of mental illness or suicide risk.
• High expectation or unrealistic demands.
• Recently suffered a lot of radiation exposure.
• Previous or current history of neoplasia or other comorbidity that could impact the patient's short-term survival.
• Patients with serious complications of coronary artery disease (e.g., perforation of interventricular septum and ventricular aneurysm and mitral regurgitation due to papillary muscle dysfunction).
• Abnormal coagulation function.
• Patients with hemodynamic instability which may lead to serious complications.
• Any condition that, in the judgment of the investigator, would place the patient at under risk.